Cilazapril

• UNSPSC Description:

  Cilazapril is a angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure. Target: ACE Cilazapril is a new nonthiol group containing angiotensin converting enzyme (ACE) inhibitor. Cilazapril has been investigated in more than 4000 patients with all degrees of hypertension, as well as in the special patient groups such as the elderly, renally impaired, and patients with concomitant diseases, such as congestive cardiac failure or chronic obstructive pulmonary disease [1]. Cilazapril is a very potent and highly effective converting enzyme inhibitor. Doses well below 5 mg/day will probably suffice for therapeutic efficacy [2].

• Target Antigen:

  Angiotensin-converting Enzyme (ACE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/cilazapril.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C([C@@H]1CCCN2N1C([C@@H](N[C@@H](CCC3=CC=CC=C3)C(OCC)=O)CCC2)=O)O

• Molecular Weight:

  417.50

• References & Citations:

  [1]Szucs, T., Cilazapril. A review. Drugs, 1991. 41 Suppl 1: p. 18-24.|[2]Nussberger, J., et al., Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol, 1987. 9(1): p. 39-44.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  88768-40-5